BioSpace News Archive

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of John Tsai, M.D., to its board of directors.

SS&C Technologies Holdings, Inc. today announced Rahul Kanwar , President and Chief Operating Officer, will present at the 25th Annual Needham Growth Conference at the Lotte New York Palace.

Longeveron Inc. today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023.

Legacy Healthcare, a clinical-stage biopharmaceutical company today announced positive results from the RAAINBOW phase 2/3 randomized placebo-controlled trial evaluating Coacillium 22.25% cutaneous solution in children and adolescents with moderate and severe alopecia areata, a debilitating autoimmune condition causing disfiguring scalp hair loss.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, announced the closing of a €130 million Series C equity financing.

While much of the mystery surrounding sepsis remains, Feinstein Institutes for Medical Research scientists published in Cellular & Molecular Immunology the discovery of a protein that inhibits the body’s ability to clear bacteria, opening new avenues of therapeutic research.

Mission Bio announced a new publication in Nature from researchers at the Ragon Institute of MGH, MIT, and Harvard and Brigham and Women’s Hospital using Mission Bio’s Tapestri® Platform to identify phenotypic signatures of hidden human immunodeficiency virus 1 -infected immune cells that allow the virus to evade immune response.

Based on hhc concept, our corporate philosophy, Eisai is committed to improve patients health outcomes and quality of life, simplify care delivery, increase health system efficiency and spur future investments in Alzheimer’s disease.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to 10 new employees with a grant date of January 3, 2023, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Assertio Holdings, Inc. announced that effective January 3, 2023, the Compensation Committee of the Company’s Board of Directors granted four newly-hired employees a total of 14,804 restricted stock units and 16,001 stock options.